Source comparison
PT-141 FDA Approved Status: Clinical vs Research Applications Comparison
FDA-approved Vyleesi for HSDD in premenopausal women NDA 210557 Fully approved (June 2019) Prescription from licensed prescriber; pharmacy dispensing record Cannot be diverted to research use; procured only through clinical distribution Compounded bremelanotid
This comparison does not assign a generated winner or score.
- FDA-approved Vyleesi for HSDD in premenopausal women
- NDA 210557
- Fully approved (June 2019)
- Prescription from licensed prescriber; pharmacy dispensing record
- Cannot be diverted to research use; procured only through clinical distribution
- Compounded bremelanotide for off-label sexual dysfunction
- 503A pharmacy compounding
- State-legal, not FDA-approved
- Individual prescription; pharmacy compounding record under state board oversight
- Cannot be repurposed for non-clinical research; human-use intent required
- Research-grade bremelanotide for in-vitro or animal studies
- Research exemption (21 CFR 312.2)
- Not FDA-approved as drug product
- Certificate of Analysis; 'for research use only' labeling; institutional documentation of non-clinical intent
- Must be sourced from peptide manufacturers, not clinical channels; no IND required for in-vitro work
- Investigational bremelanotide for unapproved human trials
- IND application (21 CFR 312)
- FDA-authorised under active IND
- Approved IND protocol; IRB approval; manufacturing under GMP; adverse event reporting
- Requires full IND submission and FDA oversight; cannot use research-grade material
- Professional Assessment
- Labs studying bremelanotide's melanocortin receptor activity, peptide stability, or neural signaling pathways operate under the research exemption. FDA approval of Vyleesi does not extend backward to cover their work, and they cannot legally procure Vyleesi or compounded versions for non-clinical use
- Compliant sourcing requires purchasing from registered peptide manufacturers offering material explicitly labeled for research, with full CoA documentation confirming purity and non-clinical intent